At the mechanistic level, RGS monotherapy and in combination with ICB sensitizes tumors to immune activation via induced immunogenic cell death (ICD), associated with upregulation of costimulatory signals (such as CD40, CD80, and ICOS-L) on melanoma cells. The gene discussed is CD40; the disease is melanoma.